Directorate Change
Futura Medical plc announces a board change with Harmesh Suniara stepping down as Non-Executive Director with immediate effect, following resolutions for a placing and subscription that will significantly reduce Lombard Odier Asset Management's shareholding. The company expresses gratitude for his guidance, particularly ahead of the fundraise which provides a secure financial footing. Futura Medical is now focused on completing its strategic review in Q1 FY26 and progressing the development of Eroxon Intense and WSD4000.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical (AIM:FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that following the passing of resolutions in respect to the recently announced placing and subscription, and significant reduction in Lombard Odier Asset Management's percentage shareholding in Futura following the upcoming admission of the placing shares and subscription shares to trading on AIM, Harmesh Suniara is stepping down from his role as Non-Executive Director and will step off the Board with immediate effect. Harmesh was appointed to the Board as Lombard Odier Asset Management's representative in March 2025.
Andrew Unitt, Non-Executive Chair, commented: "The Board would like to express our gratitude to Harmesh for his dedication to the Company during his tenure as Non-Executive Director; his advice and guidance have been invaluable ahead of the completion of the fundraise. With the successful fundraising in place giving the Company a sure financial footing, we are now focused on the competition of the strategic review in Q1 FY26, alongside progressing the development of Eroxon Intense and WSD4000."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.